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Abstract
Background:  Commercially available curcumin preparations contain a mixture of related
polyphenols, collectively referred to as curcuminoids. These encompass the primary component
curcumin along with its co-purified derivatives demethoxycurcumin and bisdemethoxycurcumin.
Curcuminoids have numerous biological activities, including inhibition of cancer related cell
proliferation and reduction of amyloid plaque formation associated with Alzheimer disease.
Unfortunately, the solubility of curcuminoids in aqueous solutions is exceedingly low. This restricts
their systemic availability in orally administered formulations and limits their therapeutic potential.
Results: Methods are described that achieve high concentrations of soluble curcuminoids in
serum. Solid curcuminoids were either mixed directly with serum, or they were predissolved in
dimethyl sulfoxide and added as aliquots to serum. Both methods resulted in high levels of
curcuminoid-solubility in mammalian sera from different species. However, adding aliquots of
dimethyl sulfoxide-dissolved curcuminoids to serum proved to be more efficient, producing soluble
curcuminoid concentrations of at least 3 mM in human serum. The methods also resulted in the
differential solubility of individual curcuminoids in serum. The addition of dimethyl sulfoxide-
dissolved curcuminoids to serum preferentially solubilized curcumin, whereas adding solid
curcuminoids predominantly solubilized bisdemethoxycurcumin. Either method of solubilization
was equally effective in inhibiting dose-dependent HeLa cell proliferation in culture. The maximum
concentration of curcuminoids achieved in serum was at least 100-fold higher than that required
for inhibiting cell proliferation in culture and 1000-fold higher than the concentration that has been
reported to prevent amyloid plaque formation associated with Alzheimer disease. Curcuminoids
were also highly soluble in solutions of purified albumin, a major component of serum.
Conclusion:  These results suggest the possibility of alternative therapeutic approaches by
injection or infusion of relatively small amounts of curcuminoid-enriched serum. They also provide
tools to reproducibly solubilize curcuminoids for analysis in cell culture applications. The
differential solubility of curcuminoids achieved by different methods of solubilization offers
convenient alternatives to assess the diverse biological effects contributed by curcumin and its
derivatives.
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Background
Turmeric is a powder derived from the root of the herb
Curcuma longa and it is commonly used as a spice and
coloring agent. Curcumin is a yellow pigment in turmeric,
where it occurs in amounts of 2–9% [1,2]. Although com-
monly referred to as 'curcumin', commercially available
preparations are actually a mixture of the principal ingre-
dient curcumin along with its copurified derivatives
demethoxycurcumin and bisdemethoxycurcumin [3].
Therefore, in this report the term 'curcuminoid' will be
used to describe such commercially available prepara-
tions.
Curcuminoids possess numerous medicinal properties.
These include antiinflammatory, antioxidant, antiviral,
antiinfective, antimalarial and wound healing properties
[4,5]. In cancer related research curcuminoids have been
used in cell culture systems, animal models, and clinical
trials [6-13]. Curcuminoids have been implicated in
inhibiting tumor promotion in skin, oral, intestinal, and
colon cancers [6]. It has also been suggested that they
inhibit breast cancer metastasis in mice [14,15]. Inhibi-
tion of cell proliferation is accomplished by cell cycle
arrest or apoptosis [7,16].
The antioxidative effect of curcuminoids and their ability
to prevent Aβ aggregation has also attracted attention in
Alzheimer disease research [17,18]. For example, orally
administered curcuminoids suppressed oxidative damage,
synaptophysin loss, and reduced Aβ deposits in rats sub-
jected to intracerebroventricular infusion of Aβ [19].
Orally administered curcuminoids have been implicated
in reducing Aβ plaque burden and the amount of soluble
Aβ in Alzheimer transgenic mice [20]. In addition, curcu-
minoids reduced interleukin-1β expression while the level
of amyloid protein precursor (APP) remained unchanged
[21]. Studies on SH-SY5Y cells showed that curcuminoids
counteracted the retinoic acid induced increased expres-
sion of APP [22] and nine curcuminoid substances iso-
lated from turmeric had differential effects of protecting
PC12 cells from Aβ insult [23]. Another study reported an
in vitro dose dependent inhibition of Aβ40 aggregation
and disaggregation of Aβ40 fibrils with curcuminoid IC50
values of 0.8 μM and 1 μM, respectively. Similar results
were obtained for curcuminoid-mediated inhibition of Aβ
fibril formation and extension, as well as fibril destabili-
zation with EC50 values ranging from 0.19 to 0.63 μM
[24]. The toxicity of Aβ to differentiated SH-SY5Y cells was
inhibited at a 1 μM curcuminoid concentration. Further-
more, peripherally injected curcuminoids were found to
cross the blood-brain barrier and orally administered cur-
cuminoids to Tg2576 mice reduced amyloid burden and
plaque formation [25].
Despite such encouraging reports, the study of curcumin-
oids is severely limited by their exceedingly low bioavail-
ability following oral administration. This is largely a
consequence of their extremely poor solubility and insta-
bility in aqueous solutions, in particular at alkaline pH
[26,27]. However, curcuminoid stability was increased in
human blood and in tissue culture media containing 10%
fetal calf serum (FCS) [28]. In clinical trials with oral
administration of curcuminoids, the observed circulating
blood or plasma concentrations were found to range from
either undetectable to about 1 μM [29-32]. Similar results
were observed in the rat [33]. In contrast, curcuminoids
are soluble to variable degrees in a number of organic sol-
vents. Curcuminoids are often prepared as a stock solu-
tion in one of these solvents, typically dimethyl sulfoxide
(DMSO) or methanol. After administering DMSO-dis-
solved curcuminoids to mice by intraperitoneal injection,
initial plasma concentrations were as high as 6 μM [34].
In cell culture studies, the curcuminoid stock solution is
usually added to the cell culture medium at various final
concentrations. Unfortunately, upon adding such predis-
solved curcuminoids to an aqueous solution they precip-
itate. Therefore, the final concentration of the actual
soluble curcuminoids in the medium remains inferential,
since it is based on the dilution of the total amount added.
Methods are here described that differentially solubilize
high concentrations of biologically active curcuminoids
in serum. This provides a novel method for curcuminoid
administration in therapeutic applications and it allows
for the preparation of tissue culture media with defined
concentrations of differentially solubilized curcuminoids.
Methods
Reagents and solutions
BSA [Fraction V, 96–99% albumin], curcuminoids
('curcumin' > 95%) [Fluka], and DMSO [ACS reagent]
were obtained from Sigma Chemical Company. 1-buta-
nol (HPLC grade) was purchased from Fisher Scientific.
Fetal calf, horse, rat, human and rabbit sera were sup-
plied by Aleken Biologicals. DMEM (high glucose),
0.05% Trypsin-EDTA, and Penicillin-Streptomycin
(10,000 units/ml, 100×) were provided by GIBCO (Inv-
itrogen). Acetonitrile and water (both HPLC grade)
were obtained from Mallinckrodt Baker Inc. All other
standard laboratory chemicals were purchased from
Research Organics.
BSA was prepared as 10% or 20% (w/v) stock solutions
in PBS (137 mM NaCl, 10 mM Phosphate, 2.7 mM KCl,
pH 7.4) and used directly or diluted as indicated. Sera
were thoroughly mixed and used as provided. Butanol
was equilibrated with an excess of deionized water and
used after phase separation. Eluent solutions A (5%
acetonitrile, 0.01% ammonium acetate, pH 4.5, and
95% water) and B (95% acetonitrile, 0.01% ammo-
nium acetate, pH 4.5, and 5% water) were used to gen-
erate a gradient in reversed phase chromatography (see
below).BMC Biotechnology 2008, 8:84 http://www.biomedcentral.com/1472-6750/8/84
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Curcuminoid solubilization and cell culture media 
preparation
Either solid curcuminoid powder in varying amounts (1–
70 mg) or 10 μl of curcuminoids (10–500 mM) predis-
solved in DMSO were added to 1 ml of serum or BSA solu-
tions in 1.5 ml microfuge tubes. Solid curcumin was
vortexed until the powder was well suspended. When
DMSO-dissolved curcuminoids were added to the aque-
ous protein solution, much of the curcuminoids precipi-
tated and the precipitate was vortexed until suspended.
Time course experiments showed that no additional cur-
cuminoid solubilization occurred after 4–6 h of incuba-
tion of the suspensions at 4°C. However, to ensure that
complete equilibrium was established, incubation was
continued on a rotary mixer for 16–24 h. Thereafter, the
remaining insoluble curcuminoids were pelleted by cen-
trifugation for 10 min at 14,000 × g. Aliquots of 200 μl
were withdrawn for butanol extraction. In all cases,
extreme care had to be exercised not to include insoluble
curcuminoids in samples designated for butanol extrac-
tions, since this would substantially increase the apparent
amount of soluble curcuminoids.
For cell culture media preparation, 29 ml of FCS were
either mixed with 870 mg (30 mg/ml) of solid curcumin-
oids or 145 μl (5 μl/ml) of DMSO containing 500 mM
curcuminoids. In both cases, the suspended curcuminoids
were stirred in 50 ml Erlenmeyer flasks at 4°C for 16–24
h. Residual insoluble curcuminoids were removed by two
centrifugations at 14,000 × g. From the resulting FCS-cur-
cuminoid solution, 1 ml was collected for butanol extrac-
tion and spectrophotometric concentration
determination, or reversed phase chromatography. Of the
remaining FCS-curcuminoid solution, 25 ml were added
to 500 ml of DMEM. The resulting media were sterilized
through 0.45 μm filters (Pall Life Sciences). Aliquots of
0.5 ml were then removed for butanol extraction and con-
centration determination. Curcuminoid-containing
media were diluted with standard medium to obtain the
desired final curcuminoid concentrations.
In experiments addressing the influence of mixing tech-
nique on curcuminoid solubility, solid curcuminoids
were added to 10 ml of FCS (30 mg/ml) and mixed either
by magnetic stirring at medium speed in a 25 ml Erlen-
meyer flask, or by rotation on a rotational mixer for 16–
24 h. Alternatively, DMSO-dissolved curcuminoids (500
mM) were added to 10 ml of FCS (5 μl/ml) and similarly
mixed.
Spectrophotometric concentration determinations and 
curcuminoid extractions
A spectral scan was generated with a 6 μM solution of cur-
cuminoids in water-saturated butanol, which was
obtained by diluting a 500 mM stock solution of curcu-
minoids dissolved in DMSO. The background absorption
scan was derived from water-saturated butanol without
curcuminoids. Aliquots of 200 μl were placed in a 96-well
microplate and scanned at 1 nm increments between
wavelengths of 370 and 460 nm in a μ Quant microplate
spectrophotometer (Bio-Tek Instruments) [Fig. 1A]. All
subsequent curcuminoid concentration determinations
were carried out at an absorption wavelength of 427 nm
and the background subtracted from the resulting optical
density (OD). A dose curve was established to correlate
spectral absorption with curcumin concentration.
Curcuminoids were extracted from 200 μl serum or BSA
solutions by mixing with 1 ml of water-saturated butanol.
Water-saturated butanol was used instead of pure butanol
because water partitions into the butanol phase at a vol-
ume ratio of slightly more then 1/10. The biphasic solu-
tion was thoroughly vortexed and phases were separated
by microcentrifugation. Aliquots of 200 μl of the upper
butanol phase were removed and either added directly to
a 96-well microplate (Corning Inc.) or further diluted
with butanol at ratios of 1:5 or 1:10 to achieve OD values
within the linear absorption range. The background OD
readings were uniformly about 0.1 (+/- 0.01) OD units
and these values were subtracted from those obtained
with the extracted curcuminoid solutions. Because of the
lower concentration of curcuminoids in cell culture
media, aliquots of 0.5 ml were extracted with 1 ml of buta-
nol. In both cases, more than 95% of the curcuminoids
uniformly partitioned into the organic phase. However,
DMEM and other tissue culture media typically contain
the indicator dye Phenol Red, which also partially parti-
tions into the butanol phase. This resulted in higher back-
ground readings of about 0.220 OD (+/- 0.02) units.
These higher background readings that in these instances
were subtracted from the experimental values did not
appreciably affect measurement accuracy or precision.
Cell culture and curcuminoid stability in media
HeLa cells (ATCC#: CCL-2) were grown in DMEM con-
taining 5% FCS and penicillin-streptomycin (100 units/
ml) at 37°C in an incubator equilibrated with 5% CO2.
For cell survival analysis, cells were seeded at about 20%
confluence in 25 cm2 flasks (Sarstedt). Cells were photo-
graphed in three random viewing fields using phase con-
trast microscopy (Minolta) and counted. The number
obtained from the initial cell count was designated as
100%. Thereafter, cells were incubated in media contain-
ing 0, 10, 20, 30, 40, and 50 μM soluble curcumin. Media
were changed and cells counted daily during three days of
incubation.
The stability of soluble curcuminoids in cell culture media
stored at 4°C was measured by extracting 0.5 ml aliquots
of media with 1 ml of butanol at indicated time intervalsBMC Biotechnology 2008, 8:84 http://www.biomedcentral.com/1472-6750/8/84
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between 0 and 28 days after preparation. Alternatively, 10
ml of media were stored in 25 cm2 flasks at 37°C in a tis-
sue culture incubator, either with or without CO2 expo-
sure. Aliquots of 0.5 ml were removed for curcuminoid
extractions at intervals ranging from 0 to 9 days. Back-
ground measurements were subtracted from identically
incubated media devoid of curcuminoids.
Sequential addition of solid and DMSO-dissolved 
curcuminoids to 5% BSA and FCS
Either 36 mg of solid curcuminoids or 12 μl of 500 mM
DMSO-dissolved curcuminoids were added to 1.2 ml of
5% BSA or FCS and processed as described. Thereafter, the
insoluble curcuminoids were pelleted by centrifugation
and the entire supernatant removed. Aliquots of 200 μl
were butanol extracted for total curcuminoid determina-
tion and 20 μl were extracted for reversed phase chroma-
tography. The remaining supernatants were mixed with
either 30 mg of solid curcuminoids or 10 μl of 500 mM
DMSO-dissolved curcuminoids in reverse order. The sus-
pensions were reincubated and then processed for con-
centration determination.
Sequential extraction of curcuminoids from 5% BSA
Solid curcuminoids in amounts of 1, 10, 20, 30, 40, and
50 mg were added to 1 ml of 5% BSA and incubated as
described above. Thereafter, the insoluble curcuminoids
were pelleted by centrifugation and the entire supernatant
removed, followed by adding 1 ml of fresh 5% BSA to the
remaining pellet. Aliquots of 200 μl were extracted with 1
ml of butanol and the concentration of total soluble cur-
cuminoids was determined. Where applicable, 20 μl aliq-
uots were analyzed by reversed phase chromatography.
This process was repeated 10 times. After the last extrac-
tion, the remaining insoluble curcuminoid pellets were
washed three times with deionized water and dried under
vacuum. The dried pellets were then dissolved in 200 μl
DMSO. Aliquots were diluted in butanol and the yield of
curcuminoids in the final pellet determined spectropho-
tometrically. Aliquots of 10 μl from the respective DMSO-
dissolved final pellets were then added to 1 ml of 5% BSA
and solubilized as described above for concentration
determination and reversed phase chromatography.
Reversed phase chromatography of soluble curcuminoids
Curcuminoids solubilized in protein solutions (20 μl) or
media samples (200 μl) were extracted for reversed phase
chromatography with 300 μl of water-saturated butanol
and evaporated in a Savant Speed-Vac concentrator
attached to a vacuum pump. The dried residue was recon-
stituted in a 0.5 ml solution containing 75% eluent A (5%
acetonitrile, 0.01% ammonium acetate, pH 4.5, and 95%
water) and 25% eluent B (95% acetonitrile, 0.01%
ammonium acetate, pH 4.5, and 5% water), representing
an acetonitrile concentration of 27.5%. Reversed phase
Spectral absorption of curcuminoids solubilized in butanol Figure 1
Spectral absorption of curcuminoids solubilized in 
butanol. A) Spectral scan of 6 uM curcuminoids in water-
saturated 1-butanol (white area) between wavelength 370 
and 460 nm with increments of 1 nm. The gray area deline-
ates the background absorption of water-saturated butanol. 
B) Dose curve of curcuminoids (1–80 μM) solubilized in 
water-saturated butanol. Data are presented as absorption 
(OD) as a function of curcuminoid concentration (μM) at a 
wavelength of 427 nm. C) Elution profile after reversed 
phase chromatography of 50 μM curcuminoids dissolved in 
27.5% acetonitrile solution (see Methods). The vertical bar 
represents 20 milliabsorption units (mAU). Elution peaks of 
curcuminoids at indicated retention times (rt) designate bis-
demethoxycurcumin (B), demethoxycurcumin (D), and cur-
cumin (C).BMC Biotechnology 2008, 8:84 http://www.biomedcentral.com/1472-6750/8/84
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chromatography was performed on an FPLC Äkta Purifier
system equipped with a Source 5RPC ST 4.6/150 column
(GE Healthcare). Reconstituted curcuminoids (300–400
μl) were loaded onto a 100 μl sample loading loop and
separated with a 35 ml linear gradient, which ranged from
a starting concentration of 75% eluent A and 25% eluent
B to a final concentration of 15% eluent A and 85% eluent
B (27.5% – 81.5% acetonitrile) at a flow rate of 1 ml/min.
The eluent was monitored at a wavelength of 427 nm.
Quantitation of individual peaks was carried out with the
Unicorn (version 2.2) peak integration program.
Concentration calculations and statistical analysis
The arithmetic mean of the molecular masses of the three
curcuminoids (338 kDa) was used as a general reference
value for spectrophotometric concentration calculations.
This was necessary since the relative contribution of each
curcuminoid varied considerably between different exper-
imental conditions. In addition, the molar absorptivity
(ε) of the three curcuminoids dissolved in ethanol were
shown to vary from 6.73 (x104 L cm-1mol-1) for curcumin
to 4.95 for bisdemethoxycurcumin at 425 nm [35]. The
molar absorptivity for the curcuminoid preparation solu-
bilized in butanol was essentially the same as that dis-
solved in ethanol (data not shown). Hence, it is likely that
similar variabilities in molar absorptivity between the
three curcuminoids dissolved in butanol exist. However,
using the arithmetic mean as a molecular mass reference
assured that the reported concentration values were
within 15% of the actual concentrations, regardless of the
relative distribution of the three curcuminoids within the
measured sample.
All data points were calculated as the average of at least
three independent experiments, each assayed in duplicate.
Error bars represent the standard deviation from the aver-
age. Where applicable, the concentration of soluble curcu-
min as a function of added curcumin was fitted to an
exponential saturation function with Sigma Plot software.
Results and discussion
Spectral properties of curcuminoids solubilized in butanol
Spectrophotometry was used to systematically determine
the concentration of soluble total curcuminoids in serum.
Since this required a reliable dose curve, it was essential to
solvent-extract the solubilized curcuminoids from the
aqueous solutions in a quantitative manner. An ideal sol-
vent proved to be water-saturated butanol, which has the
capacity to solubilize curcuminoids up to an approxi-
mately 9.5 mM concentration. This solvent is relatively
nontoxic and it has a low vapor pressure, which elimi-
nates concerns about volume changes due to evaporation
during the assay. It is also chemically inert to the polysty-
rene used in microplates. After the first extraction of 200
μl FCS-solubilized curcuminoids with 1 ml of butanol,
more than 95% of the soluble curcuminoids partitioned
into the butanol phase.
A spectral scan between wavelengths 370 nm and 460 nm
produced a maximum absorption plateau between wave-
lengths 425 nm and 431 nm (Fig. 1A). A wavelength of
427 nm was selected for concentration determinations. At
this wavelength absorption was linear at curcuminoid
concentrations between 2 and 80 μM corresponding to a
maximum optical density (OD) of about 2.5 (Fig. 1B).
A 50 μM solution of Curcuminoids in butanol was further
analyzed by reversed phase chromatography. Three
sequential peaks were eluted that were identified as curcu-
min (retention time (rt): 26 min), demethoxycurcumin
(rt: 24.8 min), and bisdemethoxycurcumin (rt: 23.6 min)
[Fig. 1C]. The identification was based on elution profiles
obtained with similar acetonitrile gradients [36-38] and
on the relative amount of each component present in the
curcuminoid mixture. Integrating the areas under the
peaks resulted in relative ratios of 79% curcumin, 18%
demethoxycurcumin, and 3% bisdemethoxycurcumin.
These values are in the same range as those reported for
other commercial preparations [29,39].
The solubility of curcuminoids in FCS differs depending on 
whether they are added in solid or DMSO-dissolved form
Using these spectrophotometric parameters, a systematic
analysis of the solubility of curcuminoids in FCS was car-
ried out (Fig. 2). Powdered solid curcuminoids in
amounts ranging from 1 mg to 70 mg were added to 1 ml
of FCS (Fig. 2A). The concentration of soluble total curcu-
minoids in FCS increased linearly to about 10 mg of
added curcuminoids. When more than 30 mg of solid cur-
cuminoids were added, saturation occurred at concentra-
tions of about 500–600 μM FCS-soluble curcuminoids.
Since a concentration of 500 μM represented only about
168 μg/ml of curcuminoids in solution, only a minute
fraction (< 1%) of the added solid curcuminoids (30–70
mg) was solubilized in FCS.
To determine whether adding a defined concentration of
curcuminoids predissolved in an organic solvent would
alter the final solubility in FCS, 10 μl of DMSO-dissolved
curcuminoids at concentrations ranging from 20 mM to
500 mM were added to 1 ml of FCS (Fig. 2B). Compared
to the results obtained by adding solid curcuminoids, the
solubility in FCS almost doubled to over 1000 μM at sat-
uration. Near-saturation levels of about 850 μM FCS-sol-
uble curcuminoids were achieved with 10 μl of 100 mM
DMSO-dissolved curcuminoids. This corresponded to
about 0.37 mg of total curcuminoids added. This was
more than 80-fold less than the comparable 30 mg of
solid curcuminoids required for near-maximum FCS-sol-
ubility (Fig. 2A). Within the linear range of the saturationBMC Biotechnology 2008, 8:84 http://www.biomedcentral.com/1472-6750/8/84
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curve for DMSO-dissolved curcuminoids (20–100 mM),
the amount of FCS-soluble curcuminoids corresponded
to about 70–85% of the total added curcuminoids. This
value was about 100-fold higher than that obtained by
adding solid curcuminoids (Fig. 2A). This indicated that
predissolving curcuminoids in DMSO rendered them in a
physical form that was more favorable for solubilization
in FCS than the solid powder.
Curcuminoids are soluble in bovine serum albumin (BSA) 
solutions
Since albumin is a major component of total serum pro-
tein, the solubility of curcuminoids in BSA solutions was
also examined. BSA was dissolved in phosphate-buffered
saline (PBS) at a concentration of 5%. One milliliter of
this solution was then incubated with solid curcuminoids
in amounts ranging from 1–70 mg (Fig. 3A). The solubil-
ity of solid curcuminoids exhibited saturation kinetics
similar to those observed with FCS. However, saturation
levels of soluble curcuminoids in 5% BSA were attained at
concentrations of about 1200–1400 μM. These concentra-
tions were more than twice as high as those achieved with
FCS (Fig. 2A) and they represented a molar ratio of curcu-
minoid/BSA of about 1.6–1.9. A similar saturation curve
was observed by adding increasing amounts of DMSO-
dissolved curcuminoids to 5% BSA solutions (Fig. 3B). In
this case, saturation occurred at curcuminoid concentra-
tions of about 2000 μM, which represented a molar curcu-
minoid/BSA ratio of about 2.7. Hence, the concentrations
at saturation obtained by adding either solid or DMSO-
dissolved curcuminoids to 5% BSA were about two-fold
higher than those achieved with FCS (Fig. 2).
When the constant amount of 30 mg solid curcuminoids
was added to 1 ml of solutions with increasing concentra-
tions of BSA (0.2–10%), saturation was observed at about
5% BSA yielding a soluble curcuminoid concentration of
about 1200 μM, which again represented a molar curcu-
minoid/BSA ratio of 1.6 (Fig. 3C). However, at BSA con-
centrations of less than 1%, curcuminoid/BSA ratios as
high as 3.3 were calculated. At higher BSA concentrations
the saturation kinetics indicated that the amount of solid
curcuminoids available for solubilization in BSA was the
limiting factor, although at a 1400 μM curcuminoid con-
centration only about 1.7% of the total added curcumin-
oids had actually been solubilized.
In contrast, when 10 μl of DMSO-dissolved curcuminoids
at a constant 500 mM concentration were added to solu-
tions with increasing concentrations of BSA, the BSA-sol-
uble curcuminoid concentration increased to a maximum
of about 4500 μM, which was obtained at BSA concentra-
tions above 14% (Fig. 3D). Within the linear range of the
curve, the molar curcuminoid/BSA ratio remained con-
stant at about 2.6. These curcuminoid/BSA ratios differ
somewhat from those reported by Barik et al. [40]. In that
study, the interaction of curcumin and BSA was studied by
fluorescence spectroscopy. The authors found that curcu-
min bound at high affinity to BSA within a microdomain
that is largely nonpolar. Their data suggested at least one,
but possibly two binding sites of curcumin in BSA. The
data reported here suggest between two and four BSA
binding sites for curcumin or its derivatives. These dis-
crepancies may be accounted for by differences in the
methods of solubilization or the concentration of curcu-
minoids in solution.
At saturating BSA concentrations (14–20%), the amount
of DMSO-dissolved curcuminoids converted into BSA-
solubilized curcuminoids was about 92–96% (Fig. 3D),
whereas the comparative value attained with solid curcu-
Solubility of curcuminoids in FCS Figure 2
Solubility of curcuminoids in FCS. A) Total curcuminoid 
solubility (μM) in 1 ml of FCS as a function of adding increas-
ing amounts (1–70 mg) of solid curcuminoids. B) Curcumin-
oid solubility (μM) in 1 ml of FCS as a function of adding 10 μl 
aliquots of DMSO-dissolved curcuminoids at concentrations 
ranging from 10 to 500 mM.BMC Biotechnology 2008, 8:84 http://www.biomedcentral.com/1472-6750/8/84
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minoids was about 1.7% (Fig. 3A). This again demon-
strated that DMSO-dissolved curcuminoids were far more
effective for solubilization than solid curcuminoids in
both FCS and BSA solutions.
Reversed ratios of solid and DMSO-dissolved curcuminoids 
in FCS and BSA solutions
The differential solubility of curcuminoids in FCS and
BSA solutions was also analyzed by reversed phase chro-
matography (Fig 4). When DMSO-dissolved curcumin-
oids were solubilized in either FCS or 5% BSA, their
relative concentrations declined in the order: curcumin
(72%) > demethoxycurcumin (23%) > bisdemethoxycur-
cumin (5%) [Fig. 4A,B]. These soluble curcuminoid ratios
were largely a reflection of the ratios in the DMSO stock
solution (Fig. 1C). In contrast, when 5% BSA or FCS was
incubated with solid curcuminoids, the elution profile of
the solubilized curcuminoids was effectively reversed.
Here, the major solubilized curcuminoid was bisdemeth-
oxycurcumin (71%) followed by demethoxycurcumin
(26%) and curcumin (3%) [Fig. 4A,B]. The effect of solu-
bilizing 30 mg of solid curcuminoids on elution profiles
was also examined when the BSA concentrations were
increased from 1% to 20%. However, this increase in BSA
concentration produced only modest changes in the cur-
cuminoid ratios. The relative amount of bisdemethoxy-
curcumin declined from 76% with 1% BSA to 64% with
20% BSA, which was reflected in a concomitant increase
in the relative amount of demethoxycurcumin from 23%
to 32%, and of curcumin from 1% to 4% (Fig 4C). These
Solubility of curcuminoids in BSA solutions Figure 3
Solubility of curcuminoids in BSA solutions. A) Curcuminoid solubility (μM) in 1 ml of 5% BSA as a function of adding 
increasing amounts (1–70 mg) of solid curcumin. B) Curcuminoid solubility (μM) in 1 ml of 5% BSA as a function of adding 10 μl 
aliquots of DMSO-dissolved curcuminoids at concentrations ranging from 10 to 500 mM. C) Curcuminoid solubility (μM) as a 
function of adding 30 mg solid curcuminoids to 1 ml of BSA solutions ranging in concentrations from 0.2 to 10%. D) Curcumin-
oid solubility (μM) as a function of adding 10 μl aliquots 500 mM DMSO-solubilized curcuminoids to 1 ml of BSA solutions 
ranging in concentrations from 0.2 to 20%.BMC Biotechnology 2008, 8:84 http://www.biomedcentral.com/1472-6750/8/84
Page 8 of 17
(page number not for citation purposes)
results show that the different methods of solubilizing
curcuminoids not only produced quantitative differences
in the total amounts solubilized, but they also resulted in
profound changes in the relative concentrations of the
individual curcuminoids.
The solubility of curcuminoids in 5% BSA and FCS depends 
on the order of addition of DMSO-dissolved and solid 
curcuminoids
This differential solubility of the curcuminoids was fur-
ther investigated by sequentially incubating 5% BSA or
FCS with either 30 mg of solid curcuminoids or with 10 μl
of 500 mM DMSO-dissolved curcuminoids. When 5%
BSA or FCS was first incubated with solid curcuminoids
followed by incubation with DMSO-dissolved curcumin-
oids, a several-fold increase in the concentration of BSA-
and FCS-solubilized curcuminoids was achieved (Fig.
5A). This level of curcuminoid solubility was higher than
that obtained by adding DMSO-dissolved curcuminoid
alone and it implied that the two additions were cumula-
tive. Conversely, when FCS or 5% BSA was first incubated
with DMSO-dissolved curcuminoids followed by solid
curcuminoids, the final concentration of soluble curcu-
minoids remained essentially constant.
The sequentially solubilized curcuminoids in FCS and 5%
BSA were also analyzed by reversed phase chromatogra-
phy. The elution profiles showed a similar pattern for
both 5% BSA and FCS (Fig. 5B,C). After the initial incuba-
tion with DMSO-dissolved curcuminoids followed by
incubation with solid curcuminoids, there was a small
increase in the relative solubility of bisdemethoxycurcu-
min and demethoxycurcumin. However, this increase was
not nearly as high as would be expected from the sum of
the incubations with solid and DMSO-dissolved curcu-
minoids alone (Fig. 5B,C). Concomitantly, there was a
small decrease in the relative amount of solubilized curcu-
min.
In contrast, when the protein solutions were first incu-
bated with solid curcuminoids followed by DMSO-dis-
solved curcuminoids the elution profile changed
dramatically. The relative levels of bisdemethoxycurcu-
min and demethoxycurcumin were essentially the cumu-
lative sum of the individually added solid and DMSO
dissolved curcuminoids in both FCS and 5% BSA. How-
ever, the relative solubility of curcumin following sequen-
tial addition was only consistent with the sum of the
individual additions to FCS (Fig. 5B). By comparison, the
relative contribution of curcumin in 5% BSA was lower
after the sequential additions than would be expected
from the sum of adding DMSO-dissolved and solid curcu-
min individually. The reason for this difference might be
due to the heterogeneous protein composition of FCS,
which may result in multiple proteins contributing to cur-
Elution profiles of curcuminoids separated by reversed phase  chromatography Figure 4
Elution profiles of curcuminoids separated by 
reversed phase chromatography. A) 30 mg of solid (left 
profile) curcuminoids or 10 μl of 500 mM DMSO-dissolved 
(right profile) curcuminoids solubilized in 1 ml of FCS. B) 30 
mg of solid (left profile) curcuminoids or 10 μl of 500 mM 
DMSO-dissolved (right profile) curcuminoids solubilized in 1 
ml of 5% BSA. C) 30 mg of solid curcuminoids solubilized in 1 
ml of 1% BSA (left profile) or 20% BSA (right profile). Vertical 
bars represent mAUs and individual curcuminoids are desig-
nated as described in Fig. 1C.BMC Biotechnology 2008, 8:84 http://www.biomedcentral.com/1472-6750/8/84
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cuminoid solubility. The data obtained by reversed phase
chromatography are in agreement with the spectrophoto-
metrically determined solubility of total curcuminoids
(Fig. 5A).
These results affirm that the mechanisms for converting
solid and DMSO-dissolved curcuminoids into BSA- and
FCS-soluble curcuminoids are profoundly different. The
reason for these differences is uncertain, in particular
since a major portion of the DMSO-dissolved curcumin-
oids initially precipitate upon addition to the aqueous
protein solution. It is conceivable that this is due to differ-
ences in structure between the added solid curcuminoids
and the curcuminoids precipitated from the DMSO solu-
tion. Commercial curcuminoids are commonly produced
by the extraction of turmeric powder with a range of
organic solvents followed by evaporation [41]. Such a
process is likely to yield ordered curcuminoid crystals or
polycrystalline structures. Solid curcuminoids would thus
allow only limited surface access of the solvent to disrupt
the defined structures. In contrast, a precipitation would
be considered a disorganized event yielding an amor-
phous solid with solvent molecules trapped between the
particles. Hence, the combination of increased surface
area for solvent access and disorganized structure would
favor enhanced solubilization of DMSO-dissolved curcu-
minoids. It is possible that this phenomenon is related to
observations made with solid dispersion experiments
using mixtures of polyvinylpyrrolidine (PVP) and curcu-
min at different ratios [42]. In that study, pure curcumin
displayed crystalline structures with well-developed
edges. In contrast, solid dispersions with varying amounts
of PVP yielded spherical particles with increased surface
area. Similarly, the solubility of curcumin in aqueous
medium increased dramatically with solid dispersions at
higher PVP/curcumin ratios [42].
Sequential extraction of solid curcuminoids reduces 
soluble yield and changes curcuminoid ratios
The differential solubility of curcuminoids was further
examined by adding solid curcuminoids in amounts of
10, 20, 30, 40, and 50 mg to 5% BSA (Fig. 6A). The insol-
uble portion of the curcuminoids was pelleted and the
supernatant removed and processed for concentration
determination as described. The remaining insoluble cur-
cuminoid pellet was reincubated with 1 ml of fresh 5%
BSA and reextracted. This procedure was repeated a total
of ten times. The amount of BSA-soluble curcuminoids
declined most rapidly during the first three incubations.
After the tenth incubation, the amount of curcuminoids
soluble in 5% BSA declined to about 15–20% relative to
the amount solubilized after the first incubation (Fig. 6A).
After the final tenth incubation, the remaining solid cur-
cuminoid pellet was rinsed three times in water and dried
under vacuum. The dried curcuminoids were dissolved in
200 μl DMSO and the concentration determined spectro-
photometrically after serial dilution of aliquots in buta-
nol. The total amount of curcuminoids in the remaining
pellets had declined by only 3–17% following ten incuba-
tions with fresh 5% BSA (Fig. 6B). Much of this decline
could be attributed to the removal of small amounts of
suspended solid curcuminoids with the supernatant.
When 10 μl of the DMSO-dissolved curcuminoids were
Sequential addition of curcuminoids to 5% BSA or FCS Figure 5
Sequential addition of curcuminoids to 5% BSA or 
FCS. A) Solid or DMSO-dissolved curcuminoids were added 
individually or sequentially to 5% BSA (left bracket) or FCS 
(right bracket) as described in Methods. After each addition 
the concentration of total soluble curcumin in the protein 
solutions was determined. B) Elution profiles of curcumin-
oids after single (DMSO, SOLID) or sequential (DMSO-
SOLID, SOLID-DMSO) addition of DMSO-dissolved 
(DMSO) or solid (SOLID) curcuminoids to 5% BSA. C) Elu-
tion profiles of curcuminoids after single or sequential addi-
tion of DMSO-dissolved or solid curcuminoids to FCS. 
Vertical bars represent mAUs and individual curcuminoids 
are designated as described in Fig. 1C.BMC Biotechnology 2008, 8:84 http://www.biomedcentral.com/1472-6750/8/84
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Sequential extraction of solid curcuminoids with 5% BSA Figure 6
Sequential extraction of solid curcuminoids with 5% BSA. A) Solid curcuminoids in amounts of 10 mg (l), 20 mg (m), 
30 mg (t), 40 mg (Ќ), and 50 mg (n) were added to 1 ml of 5% BSA. After centrifugation, the supernatant containing BSA-sol-
uble curcuminoids was removed and fresh 5% BSA was added to the remaining pellets containing insoluble curcuminoids 
(Methods). The procedure was repeated ten times and the concentration (μM) of total soluble curcuminoids determined. B) 
After the tenth extraction of solid curcumin with 5% BSA, the final pellets were washed and dissolved in 200 μl DMSO. A 10 μl 
aliquot of the DMSO-dissolved curcumin was added to 1 ml of 5% BSA and processed for concentration determination. The 
bars represent the concentration (μM) of total curcuminoids solubilized in 5% BSA. The numbers under the bars indicate the 
starting amount (mg) of the curcuminoids and the numbers in parentheses the final yield (mg) of DMSO-dissolved curcumin-
oids. C) Elution profiles of curcuminoids after first (ext.1), fifth (ext. 5), and tenth (ext. 10) extraction of 1 mg of solid curcu-
minoids. Also shown is the elution profile of the final pellet after ten extractions (residual) with 5% BSA. D) Same as in B, 
except that 50 mg of solid curcuminoids were sequentially extracted.BMC Biotechnology 2008, 8:84 http://www.biomedcentral.com/1472-6750/8/84
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added to 1 ml of 5% BSA, the amount of curcuminoids
soluble in 5% BSA was again increased to concentrations
ranging from 1500 to 2300 μM, which was consistent
with the results observed in Fig. 3.
Sequential extraction of 1 and 50 mg of curcuminoids
with 5% BSA was also monitored by reversed phase chro-
matography (Fig. 6C,D). These amounts were chosen to
detect possible variations in individual curcuminoid lev-
els due to different amounts of starting material available
for extraction. After five extractions of 1 mg of curcumin-
oids, there was a sharp decrease in the relative amount of
bisdemethoxycurcumin solubilized in 5% BSA. This
decrease was even more pronounced after ten extractions.
Concomitantly, there was an increase in the relative
amount of demethoxycurcumin after five extractions, fol-
lowed by a slight decrease after ten extractions. By com-
parison, the relative amount of solubilized curcumin
increased dramatically after five extractions and remained
largely constant thereafter, while the amount of total cur-
cuminoids available for solubilization decreased. Moreo-
ver, while there was a moderate decrease in the amount of
bisdemethoxycurcumin and demethoxycurcumin, the
overall profile of the curcuminoids remaining in the
insoluble pellet after ten extractions (Fig. 6C) was little
changed from its original composition (compare Fig. 1C).
Following the repeated extraction of the larger amount of
curcuminoids (50 mg), a different pattern emerged. While
the relative level of bisdemethoxycurcumin declined over
ten extractions, the relative amount of demethoxycurcu-
min increased after five extractions and remained con-
stant thereafter. Compared to the extraction of 1 mg
curcuminoids, the extraction of 50 mg resulted in a much
lower increase in the relative amount of soluble curcumin.
There was also less depletion of bisdemethoxycurcumin
and demethoxycurcumin in the final pellet (Fig. 6D).
These results again confirm that the three curcuminoids
exist in the preparation of solid curcuminoids in different
solid forms, such that each curcuminoid is differentially
available for solubilization in 5% BSA. The repeated
extractions of either 1 mg or 50 mg of solid curcuminoids
show that the bisdemethoxycurcumin was most readily
available for solubilization, followed by demethoxycurcu-
min. When these respective sources were depleted, curcu-
min was available for limited solubilization, while the
total amount of curcuminoids available for solubilization
was declining. Nevertheless, even after 10 extractions the
depletion of bisdemethoxycurcumin and demethoxycur-
cumin was not complete, since residual amounts
remained in the final curcuminoid pellets.
It is conceivable that the curcuminoids exist as a mixture
of pure and mixed crystals in the commercial preparations
of solid curcuminoids. Since curcumin is the most preva-
lent curcuminoid in the mixture, this compound would
be more likely to form pure crystals. It is tempting to spec-
ulate that mixed crystals are easier to solubilize than pure
crystals, resulting in the preferential solubilization of bis-
demethoxycurcumin and demethoxycurcumin from the
crystalline state. The notion that crystal structure is a pos-
sible parameter in the solubility properties of solid curcu-
min is supported by the following observation. Solid
curcumin (30 mg) was dissolved in 1 ml of acetone and
allowed to completely evaporate at room temperature.
The residual curcuminoids were then incubated with 5%
BSA and the solubilized curcuminoids analyzed by
reversed phase chromatography. The elution profile of
curcuminoids solubilized from this solid (B: 23%, D:
33%, C: 44%) differed profoundly from that obtained
from the original commercial preparation (B: 74%, D:
26%, C: 3%) [Fig 4B]. It is therefore conceivable that the
evaporation procedure had altered the original crystal
structure, thereby shifting the preferential solubilization
in 5% BSA from bisdemethoxycurcumin to curcumin.
These results also suggest that BSA may form complexes
with curcuminoids that differ in their binding affinities.
For example, when DMSO-dissolved curcuminoids are
first solubilized in 5% BSA, all high and most of the low
affinity binding sites would be occupied. Consequently,
upon further incubation with solid curcuminoids no
additional solubilization would occur, since all available
sites would already be occupied. In contrast, when 5%
BSA is first incubated with solid curcuminoids, only the
high affinity binding sites would be accessible for limited
solubilization. The remaining lower affinity sites would
then be available for subsequent solubilization of DMSO-
dissolved curcuminoids, resulting in an additive response
(Fig. 5). This concept can be extended to explain the dif-
ferent levels of solubility obtained by adding DMSO-dis-
solved or solid curcuminoids to FCS or BSA solutions
(Figs. 2 and 3), and to account for the effects of sequential
extractions of solid curcuminoids (Fig. 6).
Curcuminoids are differentially soluble in sera from 
different mammalian species
Although albumin is a major mediator of curcuminoid
solubility in serum, it is likely that other components also
contribute. A comparison of sera from different mamma-
lian species showed a high degree of variation both in
total protein and albumin contents as well as their ability
to solubilize curcuminoids. The highest level of curcumin-
oid solubility was observed in human serum followed by
horse, rabbit, rat and fetal calf serum (Fig. 7). However, in
general, curcuminoid solubility was poorly correlated
with either total protein or albumin concentration. In
addition, serum from whole rat and human blood pre-
pared in this laboratory showed a 25–50% higher curcu-BMC Biotechnology 2008, 8:84 http://www.biomedcentral.com/1472-6750/8/84
Page 12 of 17
(page number not for citation purposes)
minoid solubility than that obtained from the
commercial source. Furthermore, curcuminoid solubility
in human plasma was at least 50% lower than in serum
(data not shown). This suggests that other factors, includ-
ing the method of serum preparation or as yet unidenti-
fied individual or species-specific differences in serum
composition, contribute to curcuminoid solubility. In
addition, other serum components that were not investi-
gated, such as lipoproteins, glycoproteins, and globulins,
are also possible candidates for influencing curcuminoid
solubility.
The effect of freeze-thawing sera on curcuminoid solubil-
ity was not systematically examined here. However,
throughout the study, both FCS and BSA solutions were
frozen and thawed multiple times without apparent effect
on their ability to solubilize curcuminoids. Similarly,
serum already containing soluble curcuminoids could be
frozen and thawed without evidence of further curcumin-
oid precipitation or decline in biological activity.
The solubilization of solid curcuminoids for cell culture 
applications depends on method of mixing
Curcuminoids were solubilized in FCS for use in tissue cul-
ture medium to explore their effect on biological activity.
Specifically, 29 ml of FCS were mixed either with 870 mg of
solid or 145 μl of 500 mM DMSO-dissolved curcuminoids
for 16–24 h with a magnetic stirrer. The final concentration
of soluble curcuminoids was 966 μM for the preparation
with solid curcuminoids and 850 μM for the preparation
with DMSO-dissolved curcuminoids (Fig. 8A). Tissue cul-
ture medium was prepared by adding 25 ml of FCS-solubi-
lized curcumin to 500 ml DMEM. Final curcuminoid
concentrations were about 55 μM in the medium prepared
with solid curcumin and 51 μM in the medium prepared
with DMSO-dissolved curcumin. These measured values
were within 10% of the calculated values expected from the
dilution of FCS-solubilized curcumin (Fig. 8A).
Unexpectedly, the curcuminoid concentration achieved
by stirring solid curcuminoids was about twice as high as
that anticipated from the results described in Fig. 2. In
those experiments, 1 ml of FCS was mixed with 30 mg of
solid curcuminoids in 1.5 ml Eppendorf tubes by rotation
on a Barnstead Thermoline labquake rotator for 16–24 h.
This discrepancy in soluble curcuminoid concentrations
produced by the two methods of mixing warranted sys-
tematic investigation. Therefore, 10 ml of FCS were mixed
with 300 mg of solid or 50 μl of 500 mM DMSO-dissolved
curcuminoids either by stirring or by rotation. Indeed,
both mixing methods were similarly effective in solubiliz-
ing DMSO-dissolved curcuminoids in FCS (Fig. 8A). Con-
versely, mixing solid curcuminoids with 10 ml of FCS by
rotation resulted in lower soluble curcuminoid concentra-
tions than those produced by rotational mixing of 1 ml
samples, even though the curcuminoid/volume ratios
were the same. This could be due to less efficient mixing
of larger volumes. In contrast, stirring solid curcumin pro-
duced an almost three-fold increase in the amount of FCS-
solubilized curcuminoids (Fig. 8A). This procedure also
resulted in physical changes in the suspended solid curcu-
minoid particles. Suspended curcumin obtained by rota-
tional mixing could be effectively pelleted by low-speed
centrifugation (3000 × g), whereas much of the stirred
curcuminoids remained in suspension at this speed. This
indicated that stirring resulted in a more effective disper-
sion of solid curcuminoid particles, thus making them
available for more efficient solubilization in FCS.
Reversed phase chromatography of the DMSO-dissolved
curcuminoids solubilized in FCS by the two mixing meth-
ods revealed no differences in the levels of individual cur-
cuminoids (Fig 8B). The pattern was essentially the same
as that produced by rotational mixing of volumes of 1 ml
(compare Fig. 4B). Conversely, mixing solid curcumin-
oids by the two methods produced different curcuminoid
concentration profiles in FCS. Rotational mixing effec-
tively resulted in the same pattern as that described in Fig.
4B, whereas mixing by magnetic stirring provided higher
soluble levels of demethoxycurcumin and curcumin. Nev-
ertheless, in both cases bisdemethoxycurcumin remained
the predominant component (Fig. 8C).
Curcuminoid solubility in mammalian sera Figure 7
Curcuminoid solubility in mammalian sera. Either 30 
mg solid (white bars), or 10 μl of DMSO-dissolved curcumin-
oids at a 500 mM concentration (gray bars) were added to 1 
ml of horse, rat, rabbit, human, fetal calf (FCS) serum or 5% 
BSA solution. Brackets on top of the bars show total protein/
albumin concentrations as provided by the supplier's data 
sheets.BMC Biotechnology 2008, 8:84 http://www.biomedcentral.com/1472-6750/8/84
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This demonstrates that particle size, resulting from differ-
ent mixing methods is an important parameter in deter-
mining the relative solubility of individual and total
curcuminoids. The effect of reducing particle size is partic-
ularly relevant when solubilizing solid curcumin. It is pos-
sible that other mixing methods not examined here, such
as extended vortexing, could produce additional patterns
of curcuminoid solubilization profiles. These results sug-
gest additional parameters for differentially enriching spe-
cific curcuminoids in serum and cell culture media.
The stability of curcuminoids in tissue culture media 
depends on storage and incubation conditions
The stability of curcuminoids was investigated in cell cul-
ture media. Media prepared with solid and DMSO-dis-
solved curcuminoids were about equally stable when
stored in a refrigerator at 4°C, both declining to about
70% of the original value during a four-week period (Fig.
9A,C). However, under tissue culture conditions at 37°C,
the concentrations decreased rapidly within nine days to
30–40% for media prepared with solid curcuminoids
(Fig. 9A) and to less than 20% for media prepared with
DMSO-dissolved curcuminoids (Fig. 9C). In both cases
the decline was more rapid when media were incubated
without 5% CO2 (pH 8.0) [Fig. 9A,B]. It is likely that this
was attributable to the lower pH of the media equilibrated
with CO2 (pH 7.2). For cell culture studies, it is therefore
advisable to change media daily.
The declining stability of curcumin in solution was
defined as the loss of absorption at the wavelength of 427
nm. Curcumin was found to rapidly decompose in aque-
ous solutions, yielding the final degradation products
vanillin, ferulic acid, and feruloyl methane [27]. These
compounds have shifted their absorption maximum to
the UV range and they no longer absorb at the wavelength
of 427 nm. Thus, the decrease in absorption at 427 nm
can be considered a reliable measure of the stability-
related decline in curcumin concentration, in particular
since it was accompanied by a proportional decline in
biological effect on cells in culture (data not shown).
These conclusions were supported by reversed phase chro-
matography of curcuminoids from media incubated at
37°C in the presence of 5% CO2. In media containing
serum prepared with stirred solid curcuminoids, the start-
ing profile was the same as that shown in Fig. 8. The pre-
dominant component was bisdemethoxycurcumin with
lower amounts of demethoxycurcumin and curcumin
(Fig. 9B). During a seven-day incubation, all components
declined in concentration. However, the most rapid
decline was observed with curcumin and demethoxycur-
cumin. The most stable component was bisdemethoxy-
curcumin, which after seven days had declined by only
about 50% (Fig. 9B).
Cell culture media preparation and curcuminoid solubiliza- tion in FCS produced by different mixing techniques Figure 8
Cell culture media preparation and curcuminoid sol-
ubilization in FCS produced by different mixing tech-
niques. A) Solutions for cell culture media were prepared by 
adding either solid (white bars) or DMSO-dissolved (500 
mM) curcuminoids (gray bars) to FCS. The FCS was subse-
quently added to DMEM at a final concentration of 5%. The 
total curcuminoid concentrations in the media were then 
determined by butanol extraction. The measured (meas.) val-
ues were compared to the calculated (calc.) values (brackets) 
for both media prepared with solid (white bars) and DMSO-
dissolved (gray bars) curcuminoids. On the right side of the 
panel DMSO-dissolved (gray bars) or solid curcuminoids 
(white bars) were mixed with FCS either by stirring or by 
rotation. The total amount of total curcuminoids solubilized 
by either method was determined spectrophotometrically. 
B) Elution profiles after separation by reversed phase chro-
matography of DMSO-dissolved curcuminoids solubilized in 
FCS, mixed either by stirring (right) or rotation (left). C) Elu-
tion profiles of solid curcuminoids solubilized in FCS, mixed 
either by stirring (right) or rotation (left).BMC Biotechnology 2008, 8:84 http://www.biomedcentral.com/1472-6750/8/84
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In media containing serum prepared with DMSO-dis-
solved curcuminoids, the starting concentration of the
individual curcuminoids (Fig. 9D) reflected the curcu-
minoid ratios present in the original powdered mixture
(Fig. 1C). Curcumin, which at the onset was the predom-
inant component, declined rapidly in relative concentra-
tion and became undetectable after seven days of
incubation. The level of demethoxycurcumin declined
less rapidly from a lower initial concentration. Bisdemeth-
oxycurcumin was again the most stable component and
its concentration declined moderately from what had
been a very low initial concentration (Fig. 9D). In media
prepared either with solid and DMSO-dissolved curcu-
minoids, the stability of the individual components
declined in the order: bisdemethoxycurcumin > demeth-
oxycurcumin > curcumin. The sum of the concentration
declines of the individual curcuminoids observed by
reversed phase chromatography (Fig. 9A,C) was in agree-
ment with the values obtained by spectrophotometry of
the total curcuminoids (Fig. 9B,D).
The effects on cell proliferation of media prepared with 
solid and DMSO-dissolved curcuminoids are 
indistinguishable
Media containing serum prepared with either solid or
DMSO-dissolved curcuminoids were compared for their
effect on cell growth and survival. The freshly prepared
media were diluted with curcuminoid-free medium to 0,
10, 20, 30, 40, or 50 μM concentrations of curcuminoids.
HeLa cells were seeded at a density of about 20% conflu-
ence (designated as a relative starting cell number of
100%) and then incubated at these curcuminoid concen-
trations for three days. The results were indistinguishable
for media prepared either with solid curcuminoids or with
DMSO-dissolved curcuminoids (Fig. 10). Without curcu-
minoids, HeLa cells divided exponentially with a dou-
bling time of about 26 h. At a concentration of 10 μM
curcuminoids cell division continued during the three
days of incubation, although at a slower rate with a dou-
bling time exceeding 48 h. At curcuminoid concentrations
between 20 μM and 50 μM cell survival declined to zero
after three days in a dose dependent manner (Fig. 10A,B).
Stability of curcuminoids in cell culture media Figure 9
Stability of curcuminoids in cell culture media. A) Stability of curcuminoids in media prepared with solid curcuminoids. 
The media were either stored at 4°C (m) or in a cell culture incubator at 37°C, with () or without (Ќ) exposure to 5% CO2. 
B) Elution profiles after reversed phase chromatography of media prepared with solid curcuminoids at day 0, day 3, and day 7 
of incubation at 37°C with 5% CO2. C) Same as in panel A, except that the media were prepared with DMSO-dissolved curcu-
minoids. The media were stored at 4°C (l) or in a cell culture incubator at 37°C with (s) or without (t) 5% CO2. D) Same 
as in panel B except that the media were prepared with DMSO-dissolved curcuminoids.BMC Biotechnology 2008, 8:84 http://www.biomedcentral.com/1472-6750/8/84
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In other reported cell culture studies, curcumin inhibited
cell growth or induced apoptosis in a variety of cell lines
at concentrations ranging from 10–100 μM [43-49]. The
presented data concur with those results. Although the
ratios of the individual curcuminoids were different in
media prepared with solid or DMSO-dissolved curcumin-
oids, there was no detectable difference in their ability to
inhibit HeLa cell proliferation under the culture condi-
tions used here. Similar results were observed in a variety
of cell lines [50]. These cell culture studies also suggest
that curcuminoid levels required for efficient control of
cell proliferation are vastly higher than those obtained in
plasma by oral uptake [51].
Conclusion
Methods are described that enable the solubilization of
curcuminoids at high concentrations in serum or albumin
solutions. The serum-solubilized curcuminoids can be
quantitatively extracted with water-saturated butanol and
their concentration determined spectrophotometrically at
427 nm. Once curcuminoids are dissolved, the serum can
be diluted or concentrated at will without evidence of pre-
cipitation (data not shown). This allows for the prepara-
tion of cell culture media with precisely defined
curcuminoid concentrations. The concentration of total
curcuminoids that can be achieved in serum is about 100-
fold higher than that required for inhibition of cell prolif-
eration activity in cell culture systems [43-49]. This imme-
diately suggests a novel method for curcuminoid
administration by intravenous infusion of serum-solubi-
lized curcuminoids, thereby circumventing the gastroin-
testinal tract. For example, if a typical human subject has
a total blood volume of 5 liters, an intravenous infusion
of only 50 ml serum would achieve an initial blood con-
centration of about 20–30 μM, an amount compatible
with inhibition of cell proliferation in culture. Such
defined high concentrations would also allow for the
study of the metabolism and partition of curcuminoids
into various fluid compartments to obtain optimal
steady-state therapeutic levels of curcuminoids. The
potential toxic effects associated with DMSO in these
instances should be considered negligible, since the
amount administered is a minute fraction of that consid-
ered acceptable in e.g. stem cell transplantation and blood
progenitor cell cryopreservation [52,53]. However, the
potential toxic effects of curcuminoids would have to be
further investigated at such unprecedented plasma con-
centrations. Moreover, studies relating to the effect of cur-
cumin on Alzheimer disease suggest that therapeutic or
preventative effects could be achieved in as little as a 1–2
μM concentration range [23-25], which is less than 1/10
of that required for inhibiting tumor proliferation in cell
culture. At these lower concentrations toxic effects are
much less likely to occur.
In addition to providing generally high concentrations of
soluble curcuminoids, the described procedures offer the
opportunity to adjust the level of individual curcumin-
oids in serum preparations. For example, if solid curcu-
min is used to prepare serum, the predominant
solubilized curcuminoid is bisdemethoxycurcumin,
whereas curcumin predominates when DMSO-dissolved
curcuminoids are used. Variations in mixing techniques
for solubilizing solid curcuminoids in serum offer addi-
tional alternatives for maximizing solubility and modify-
Effect of curcuminoids on cell proliferation Figure 10
Effect of curcuminoids on cell proliferation. A) Cell 
survival (%) after incubating HeLa cells in media without cur-
cumin (m) or with media prepared with solid curcumin at 
concentrations of 10 (), 20 (Ќ), 30 (), 40 (), or 50 μM 
(+). The initial seeding density of the HeLa cells was about 
20% confluence for all cells, which was assigned the relative 
value of 100%. Cells were counted daily for three days and 
the data points represent average cell numbers from four dif-
ferent viewing fields with standard deviations (error bars). B) 
Same as in panel A, except that cells were incubated in media 
prepared either without curcumin (l) or with medium pre-
pared with DMSO-dissolved curcumin at concentrations of 
10 (n), 20 (t), 30 (s), 40 (), or 50 μM (l).BMC Biotechnology 2008, 8:84 http://www.biomedcentral.com/1472-6750/8/84
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ing curcuminoid ratios. Furthermore, curcuminoids
solubilized in sera by different methods can be combined
to achieve optimal curcuminoid ratios for specific treat-
ment regiments or cell culture applications.
Abbreviations
FCS: fetal calf serum; BSA: bovine serum albumin; PBS:
phosphate-buffered saline; DMSO: dimethylsulfoxide;
APP: amyloid precursor protein; DMEM: Dulbecco's Mod-
ified Eagle Medium; OD: optical density; ATCC: American
Type Culture Collection; PVP: polyvinylpyrrolidine; rt:
retention time; mAU: milliabsorption units.
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